Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic Leukemia
Sponsor: Anhui Provincial Children's Hospital
Summary
This is a prospective, multicenter, real-world study of 500 participants with childhood acute lymphoblastic leukemia who are scheduled to receive dolasetron mesylate injection for prophylaxis against chemotherapy-induced nausea and vomiting. This study did not make any decision or process intervention for clinical antitumor therapy. The study plans to observe the control of nausea and vomiting within 120 h (D1-D5) after receiving induction chemotherapy and the safety within 7 days (or until this discharge, whichever occurs first). During the whole study, demographic data, history of motion sickness, ECOG score, complications, name and dosage of anti-tumor therapy drugs, this antiemetic regimen, nausea and vomiting, rescue therapy drugs, combined drugs and adverse events were recorded.
Official title: Prospective, Multicenter, Real-world Study of Dolasetron Mesylate Injection for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children With Acute Lymphoblastic Leukemia
Key Details
Gender
All
Age Range
2 Years - 17 Years
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2024-11-21
Completion Date
2025-12-31
Last Updated
2025-01-01
Healthy Volunteers
No
Conditions
Interventions
Dolasetron mesylate injection
1.8 mg/kg Dolasetron mesylate injection should be injected intravenously 30±10 min before chemotherapy infusion, with the maximum dose not exceeding 100 mg. It can also be mixed with apple juice or apple-grape juice for oral use, the oral dose is 1.8 mg/kg, the maximum amount is not more than 100 mg, taken orally within 1 h before chemotherapy. Other antiemetic drugs, except dolasetron, are at the discretion of the subject's supervising physician in accordance with clinical practice.
Locations (1)
Anhui Children's Hospital
Hefei, Anhui, China